RINVOQ: A Quick Introduction
Learn from experts in gastroenterology on the importance of mucosal healing in clinical practice, and how RINVOQ performed on mucosal healing as a secondary endpoint during a Phase 3 clinical trial program.
Professor Subrata Ghosh talks about how mucosal healing can be measured, its importance in the management of ulcerative colitis, and why it is a valuable treatment goal in clinical practice.
Professor Remo Panaccione discusses two mucosal endpoints (mucosal healing and endoscopic remission) from a recent Phase 3 clinical trial program looking at RINVOQ for the treatment of adults with moderately to severely active UC.
Doctor Walter Reinisch discusses the histologic endoscopic healing rates gathered from RINVOQ’s moderately to severely active UC Phase 3 clinical trial program.
Take a look at this introduction to RINVOQ video for patients prescribed RINVOQ. This video is supplementary to the Patient Information Leaflet.
Watch Professor Edouard Louis discuss results from a Phase 3 clinical trial program that evaluated RINVOQ as an induction and maintenance therapy for adults with moderately to severely active UC.
Learn more about RINVOQ’s safety profile during a Phase 3 8-week induction and 52-week maintenance clinical study program in UC.
Learn more about the mechanism of action of RINVOQ in ulcerative colitis.
Hear a rheumatologist and a dermatologist discuss their experiences using RINVOQ with their patients.
Previous
Next
[Affiliate to determine which video(s) to include according to local regulations]
Meet three moderately to severely active UC patients* (Andrew, Meera and Issac), and learn more about how RINVOQ treatment could be helpful to them.
*Hypothetical patient cases.
Patient profile:
Andrew
Patient profile:
Meera
Patient profile:
Issac
[Affiliates to insert content once available, subject to approval and as applicable per local regulations]
JAK: Janus kinase; UC: ulcerative colitis.
REFERENCES
- RINVOQ Summary of Product Characteristics.
- Danese S, Vermeire S, Zhou W, et al. Lancet. 2022;399(10341):2113–2128.